Effects of Aqueous Extracts of *Cynanchum wilfordii* in Rat Models for Postmenopausal Hot Flush

Gyuok Lee¹,², Chul-yung Choi², and Woojin Jun¹

¹Division of Food and Nutrition, Chonnam National University, Gwangju 61186, Korea
²Jeollanamdo Institute of Natural Resources Research, Jeonnam 59338, Korea

**ABSTRACT:** Menopausal hot flushes (HFs), which manifest as a transient increase in skin temperature, occur most frequently in postmenopausal women, and sometimes negatively influence daily life. We investigated the effect of an aqueous extract of *Cynanchum wilfordii* (CWW) in a rat model of menopausal HFs, where tail skin temperature (TST) is increased after the rapid estrogen decline induced by ovariectomy. Ten-week-old female rats were ovariectomized and treated with CWW for 1 week. We measured TST and rectal temperatures (RT) and investigated serum estradiol. The TST in ovariectomized (OVX) rats was significantly elevated after ovariectomy compared with control rats, whereas the RT in OVX rats was not elevated. Administration of CWW (200 mg/kg/d for 7 days, p.o.) significantly improved the skin temperature increase in OVX rats. The lower level of serum estradiol in OVX rats was significantly increased by supplying E2, but it was not affected by CWW. The present study indicates a need for future research involving treatment with high concentrations of *C. wilfordii* and measurement over 24 h.

**Keywords:** anti-hot flush, *Cynanchum wilfordii*, tail skin temperature, ovariectomy

**INTRODUCTION**

Hot flushes (HFs) are the most common postmenopausal symptom and are reported as feelings of intense warmth along with sweating, flushing, shivering, and chills. HFs usually last for 1–5 min, with some lasting as long as an hour (1). The physiology of HFs on temperature regulation are not known in detail, but probably involves core body temperature, central processing areas in the central nervous system, neuromodulators, peripheral vasculature, and sweat glands (2). A HF occurs as a transient increase in skin temperature, associated with objective signs of cutaneous vasodilation and vasoconstriction when the core temperature drops. Accumulating evidence regarding the etiology of HFs suggests that vasomotor instability associated with a significant withdrawal of estrogen is the base for the pathophysiology (3-5). It is well known that estrogen has anti-inflammatory and vasoprotective effects, modulates vascular physiology and function in vitro, in vivo, and in human models (6-11). For many years, estrogen-based hormone therapy has been an effective treatment for HFs. However, results obtained from numerous clinical trials indicated increased problems of thromboembolic incidents, heart disease, and breast cancer in women receiving long-term hormone replacement therapy (12). As an alternative to hormone replacement therapy, selective serotonin reuptake inhibitors and venlafaxine have been introduced as primary therapy for HFs (13). Regrettably, selective serotonin reuptake inhibitors can interrupt the metabolism of tamoxifen in patients with breast cancer (14). Accordingly, the development of effective and safe non-hormonal treatments for patients with menopausal syndromes (including HFs) is required.

*Cynanchum* is a genus of about 200 species that are widely distributed in Asia. Most *Cynanchum* species are used in traditional herbal medicine in Korea for the prevention and treatment of various diseases such as rheumatic arthritis, geriatric diseases, atherosclerotic vascular diseases, and ischemia-induced diseases (15). *C. wilfordii* Radix is described as the roots of *C. wilfordii* in Korean pharmacopoeia. In a previous human study, it was reported that a combination of EstroG (C. wilfordii, Angelica gigas, and Phlomis umbrosa), vitamin, and minerals improved various menopausal associated disorders (16).

In a clinical trial, EstroG-100 appeared to be an effective and safe dietary supplement for use in pre-, peri-, and
post-menopausal women (15). Unfortunately, there is currently little research on improving HFs with C. wilfordii in vivo.

Therefore, the present study was designed to study the anti-HF effect of C. wilfordii in an ovariectomized rat model.

**MATERIALS AND METHODS**

**Samples and preparation**

*C. wilfordii* root (2 kg) was extracted with distilled water at 100°C for 4 h, 0.7~0.75 kgf/cm². The extract was filtered through Whatman No. 4 filter paper and concentrated in vacuum at 40°C using a rotary evaporator (R-210, BÜCHI Labortechnik AG, Flawil, Switzerland). The extracted compound was lyophilized using a freeze-dryer and was stored at −20°C until needed. The aqueous extract of *C. wilfordii* was defined as CWW, which was used for treatments. Chemicals used were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA).

**Animals and treatments**

This study was approved by the Animal Ethical Committee of Jeollanamdo Institute for Natural Resources Research (JINR1515). All experimental procedures were undertaken in compliance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, Bethesda, MD, USA) and the National Animal Welfare Law of the Republic of Korea. Ten-week-old female Sprague-Dawley rats weighing 210~230 g were purchased from Samtako (Osan, Korea). The animals were allowed tap water and standard laboratory food *ad libitum*, and were housed in polycarbonate cages at a temperature of 23±2°C, relative humidity of 55±10% and a 12-h light/dark cycle, with lights on from 07:00 h to 19:00 h daily. The rats were randomly allocated to two groups before the operation. Both groups were anesthetized with Zoletil 50 (Virbac, Carros, France) 50 mg/kg IP. Then, one group received bilateral ovariectomy using the dorsal approach (OVX; n=45) and the other group underwent a sham operation (sham; n=7) as controls. The OVX rats were randomly divided into 4 groups: OVX group (OVX/vehicle; n=9), E2 treatment group (OVX/E2; n=9), and two CWW treatment groups (OVX/CWW100 or 200; n=9). CWW (100 or 200 mg/kg body weight/d), E2 (91 μg/kg body weight/d) or distilled water were orally administered to rats at 0.05 mL/kg body weight once a day for 7 days, starting 1 week post surgery. Distilled water (10 mg/kg) as the control was administered to the sham-operated rats for 7 days following the same schedule.

**Experimental procedure**

Rats underwent bilateral ovariectomy or sham operations. After 1 week recovery period, CWW or E2 was administered once daily by oral gavage for 7 days. On the measurement day, water, E2, or CWW were administered orally 30 min before tail skin temperature (TST) and rectal temperature (RT) measurements. After the measurement of TST and RT, rats were sacrificed and then blood was collected to measure serum estradiol levels.

**Measurement of TST and RT**

Rats were restrained in a holder in a conscious state and the TST was measured for 1 h at the dorsal surface of the tail about 2 cm from the fur line with an infrared thermometer (AMIR 7210, Ahlborn Messtechnik GmbH, Holzkirchen, Germany). Before testing, all animals were settled in the laboratory room for 15 min. The environment temperature was 25°C. Measuring points were identified and marked on the dorsal surface of the tail 2 cm from its base. TST data were measured at 10 min intervals throughout the experimental period. TST during the 1 h measurement period was calculated and data were analyzed as the change in TST for each 10 min measurement compared with the mean TST at 0 min. Changes in TST were assessed using ∆TST.

\[
\Delta TST = (TST \text{ in each 10 min block}) - (TST \text{ at 0 min})
\]

Values were expressed as the means±standard error of the mean (SEM).

RT was measured with a microprobe thermometer (BAT-12, Physitemp, Clifton, NJ, USA) inserted 5 cm into the rectum. The probe, dipped into glycerol before insertion, was held in the rectum for about 20 s. Measurements were taken at each location twice. Temperature recordings were carried out by the same person that handles the animals prior to the experiment.

\[
\Delta RT = (RT \text{ in each 10 min block}) - (RT \text{ at 0 min})
\]

Values were expressed as mean±SEM.

Both TST and RT were measured every 10 min for 1 h, and their mean values were calculated for data analysis.

**Assay for serum chemistry**

For the measurement of individual serum E2 concentrations, blood samples were collected via abdominal aorta puncture and were kept at room temperature for 30 min followed by centrifugation at 3,000 rpm for 10 min. Serum samples were stored at −80°C until assayed. Steroids from serum samples were extracted with diethyl ether twice and concentrated for estradiol determination. The level of estradiol was measured using a competitive ELISA assay Kit (ADI-901-174, Enzo Life Scien-
Anti-Hot Flush Effects of CWW

Fig. 1. Changes of the tail skin temperature (TST) in the ovariec-
tomised (OVX) rats. Aqueous extract of *Cynanchum wilfordi*
(CWW), E2, and distilled water (vehicle) were orally adminis-
tered to rats once a day for 7 days starting one week after
surgery. Shown are the mean changes in TST compared with
the mean calculated at 0 min (ΔTST). Data are presented as
the mean±SEM. Significantly different at ##P<0.01 compared
with the sham/vehicle group and *P<0.05 and **P<0.01 com-
pared with OVX/vehicle group.

Fig. 2. Changes of the rectal temperature (RT) in the ovariec-
tomised (OVX) rats. Aqueous extract of *Cynanchum wilfordii*
(CWW), E2, and distilled water (vehicle) were orally adminis-
tered to rats once a day for 7 days starting one week after
surgery. Shown are the mean changes in RT compared with
the mean calculated at 0 min (ΔRT). Data are presented as
the mean±SEM.

Fig. 3. Changes in serum estradiol levels in the ovariectomised
(OVX) rats. Each value is expressed as the mean±SEM. Signifi-
cantly different at #P<0.05 compared with the sham/vehicle
group and *P<0.05 compared with OVX/vehicle group. CWW,
aqueous extract of *Cynanchum wilfordii*.

ces, Farmingdale, NY, USA) according to the manufac-
turer’s instructions. The limit of detection for the assay
was 14.0 pg/mL.

Statistical analysis
All values represent as the mean±SEM. The statistical
significance was evaluated by a one-way analysis of var-
iance (ANOVA) followed by Dunnett’s test or Fisher’s
F-test. The significance level was accepted at P<0.05.

RESULTS AND DISCUSSION

The results of the change of TST are presented in Fig. 1. The
ΔTST was maximally 50 ~ 60 min after measurement
and those of the sham/vehicle rats were lower than those
of the OVX rats. Either CWW rats (100 or 200 mg/kg)
were significantly (P<0.05) lower than that of the OVX/
vehicle group. E2 treatment (OVX/E2) significantly (P<
0.01) inhibited the elevation of skin temperature in
OVX rats, as did the 200 mg/kg dose of CWW. Howev-
er, a difference in the dose-response curves seen for
ΔTST was not observed among CWW-treated groups. As
shown in Fig. 2, there were no differences in ΔRT
among any of the groups during the measurement peri-
d.

The serum concentrations of estradiol in OVX and
sham-operated rats are shown in Fig. 3. The estradiol lev-
el in sham rats was significantly higher (P<0.05) than in
OVX rats. The lower level of estradiol was significantly
(P<0.05) increased by supplying E2 (91 µg/kg, p.o.), but
it was not affected by treatment with CWW.

HF's in women are generally considered a thermoreg-
ulatory event, with the vasomotor symptoms and in-
creased sweating being consistent with a heat dissipation
response. The majority of HF's are preceded by an in-
crease in core body temperature and their incidence is
higher in a warm situation or following heating or exer-
cise (17). It has been hypothesized that this thermoreg-
ulatory response is due to a dramatically narrowed ther-
moregulatory neutral zone, meaning that even a very
small change in core body temperature may cross the
temperature threshold for a heat dissipation response
(18). This thermoregulatory process of HF's has led to the
assumption that they are generated in the thermoregula-
try areas of the anterior hypothalamus, as this area
contains neurons that monitor and regulate body tem-
perature. However, although the central thermoregula-
try regions of the brain may be involved, there is no evi-
dence as to the pathophysiology of HF's. Research into
the role of estrogen withdrawal in HF's has generally as-

sumed it to be a central effect, but there is little direct experimental evidence.

There has been growing attention to the use of phytoestrogens as ‘alternative’ therapies for HFs. However, limited evidence from small randomized controlled trials provides mixed results suggesting that soy protein and isolated isoflavones do not substantially improve HFs (4).

Flushing of the tail skin in OVX animals is regarded as a good indicator for climacteric HFs, although the spontaneous appearance of flushing is irregular. After ovariectomy, TST increases, and this effect can be reduced by supplying estrogen (19-23). RT has been reported to lower, to increase, or to have no effect. These conflicting results may be caused by differences in environmental factor (restrained or free-moving condition, measurement period, etc.) (24-26). In this paper, *C. wilfordii* inhibited the elevation of skin temperature in OVX rats, but *C. wilfordii* did not restore the lowered serum estrogen in OVX rats. These findings suggest that *C. wilfordii* does not confer estrogenic activity to serum, and it does not potentiate estrogen-production in the extra ovarian tissue in OVX rats. This is consistent with human studies, which showed that serum estadiol levels in the EstroG-100 group did not change, implying that EstroG-100 was not an active estrogenic compound (15). Some plants contain substances called “phytoestrogens”, such as isoflavones (27) and coumestrol (28,29), that activate estrogen-controlled functions via estrogen receptors. In addition, raloxifene, which is a synthetic selective estrogen receptor modulator (SERM), exhibits antiestrogenicity in the breast and uterus, but acts as an agonistic in the bone and liver (30). If such phytoestrogen-like or SERM-like substances are contained in *C. wilfordii*, the estrogen-like activity regarding thermoregulation may be induced without restoring the decreased serum estrogen level in OVX rats. Accordingly, further experiments are required to determine the anti-HFs effect of *C. wilfordii* at higher doses and to search for other possible mechanisms such as neuromodulators.

In conclusion, *C. wilfordii* inhibited the potentiation of skin temperature elevation in OVX rats. The present study results also suggest that estrogen is useful as hormone replacement therapy for menopausal hot flashes.

**AUTHOR DISCLOSURE STATEMENT**

The authors declare no conflict of interest.

**REFERENCES**

1. Kronenberg F. 1990. Hot flashes: epidemiology and physiology. *Ann NY Acad Sci* 592: 52-86.
2. Shen W, Stearns V. 2009. Treatment strategies for hot flushes.
skin temperature in two rodent models of estrogen deficiency-related thermoregulatory dysfunction. *Brain Res* 1028: 191-202.

23. Bowe J, Li XF, Kinsey-Jones J, Heyerick A, Brain S, Milligan S, O'Byrne K. 2006. The hop phytoestrogen, 8-prenylnaringenin, reverses the ovariectomy-induced rise in skin temperature in an animal model of menopausal hot flushes. *J Endocrinol* 191: 399-405.

24. Wright BE, Katovich MJ. 1996. Effect of restraint on drug-induced changes in skin and core temperature in biotelemetered rats. *Pharmacol Biochem Behav* 55: 219-225.

25. Freedman RR, Norton D, Woodward S, Cornélissen G. 1995. Core body temperature and circadian rhythm of hot flashes in menopausal. *J Clin Endocrinol Metab* 80: 2354-2358.

26. Kobayashi T, Tamura M, Hayashi M, Katsuura Y, Tanabe H, Ohta T, Komoriya K. 2000. Elevation of tail skin temperature in ovariectomized rats in relation to menopausal hot flushes. *Am J Physiol Regul Integr Comp Physiol* 278: R863-R869.

27. Morito K, Hirose T, Kinjo J, Hirakawa T, Okawa M, Nohara T, Ogawa S, Inoue S, Muramatsu M, Masamune Y. 2001. Interaction of Phytoestrogens with Estrogen Receptors α and β. *Biol Pharm Bull* 24: 351-356.

28. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA. 1998. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. *Endocrinology* 139: 4252-4263.

29. Diel P, Oliff S, Schmidt S, Michna H. 2001. Molecular identification of potential selective estrogen receptor modulator (SERM) like properties of phytoestrogens in the human breast cancer cell line MCF-7. *Planta Med* 67: 510-514.

30. Jisa E, Dornstauder E, Ogawa S, Inoue S, Muramatsu M, Jungbauer A. 2001. Transcriptional activities of estrogen receptor alpha and beta in yeast properties of raloxifene. *Biochem Pharmacol* 62: 953-961.